Evaluation of Immunogenicity of LY2963016 Insulin Glargine Compared with Lantus® Insulin Glargine in Patients with Type 1 Diabetes Mellitus or Type 2 Diabetes Mellitus.

CONCLUSIONS: LY IGlar and IGlar have similar immunogenicity profiles; anti-insulin glargine antibody levels were low for both treatments with no observed effect on efficacy and safety outcomes. PMID: 26434665 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26434665?dopt=Abstract

Source: Diabetes Metab - October 5, 2015 Category: Endocrinology Authors: Ilag LL, Deeg MA, Costigan T, Hollander P, Blevins TC, Edelman SV, Konrad RJ, Ortmann RA, Pollom RK, Huster WJ, Zielonka JS, Prince MJ Tags: Diabetes Obes Metab Source Type: research